{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:24:37Z","timestamp":1770729877010,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.hoc.2024.05.016","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T11:32:55Z","timestamp":1721734375000},"page":"997-1010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Progress in Immune Checkpoint Inhibitor for Melanoma Therapy"],"prefix":"10.1016","volume":"38","author":[{"given":"Celine","family":"Boutros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Herrscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.hoc.2024.05.016_bib1","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.016_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.016_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2024.05.016_bib4","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.016_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.016_bib6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s43018-021-00276-8","article-title":"LAG-3 and PD-1 blockade raises the bar for melanoma","volume":"2","author":"Robert","year":"2021","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.016_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.016_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41571-022-00602-8","article-title":"LAG3 inhibition improves outcomes","volume":"19","author":"Sidaway","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2024.05.016_bib9","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"10240","key":"10.1016\/j.hoc.2024.05.016_bib10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.016_bib11","doi-asserted-by":"crossref","first-page":"e003743","DOI":"10.1136\/jitc-2021-003743","article-title":"Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067","volume":"9","author":"Regan","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.hoc.2024.05.016_bib12","doi-asserted-by":"crossref","first-page":"e397478","DOI":"10.1200\/EDBK_397478","article-title":"Evolving management of stage IV melanoma","volume":"43","author":"Switzer","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.016_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/OP.23.00675","article-title":"Systemic therapy for melanoma: ASCO guideline update Q and A","volume":"20","author":"Sondak","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.016_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.016_bib15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.016_bib16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/cancers15051542","article-title":"Melanoma brain metastases: a retrospective analysis of prognostic factors and efficacy of multimodal therapies","volume":"15","author":"Intern\u00f2","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"32","key":"10.1016\/j.hoc.2024.05.016_bib17","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.016_bib18","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2024.05.016_bib19","doi-asserted-by":"crossref","unstructured":"Long G.V., Atkinson V., Lo S., et al., Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). J Clin Oncol, 39 (15_suppl). https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9508.","DOI":"10.1200\/JCO.2021.39.15_suppl.9508"},{"issue":"17","key":"10.1016\/j.hoc.2024.05.016_bib20","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-21-1046","article-title":"Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases","volume":"27","author":"Di Giacomo","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.016_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s11912-023-01429-x","article-title":"Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma","volume":"25","author":"Boutros","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.016_bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.016_bib23","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S1470-2045(23)00334-0","article-title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study","volume":"24","author":"Dummer","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.016_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.onc.1207007","article-title":"Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase","volume":"23","author":"Pak","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2024.05.016_bib25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/EDBK_200819","article-title":"New Era in the Management of Melanoma Brain Metastases","volume":"38","author":"Tawbi","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.016_bib26","doi-asserted-by":"crossref","first-page":"MMT39","DOI":"10.2217\/mmt-2019-0022","article-title":"Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review","volume":"7","author":"Miller","year":"2020","journal-title":"Melanoma Manag"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.016_bib27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2024.05.016_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.hoc.2024.05.016_bib29","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.016_bib30","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial [published correction appears in Lancet Oncol. 2021 Oct;22(10):e428]","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2024.05.016_bib31","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"33","key":"10.1016\/j.hoc.2024.05.016_bib32","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG\/KEYNOTE-054 Trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.016_bib33","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.2217\/fon-2019-0666","article-title":"KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma","volume":"16","author":"Luke","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.hoc.2024.05.016_bib34","author":"Luke"},{"issue":"19","key":"10.1016\/j.hoc.2024.05.016_bib35","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10427","key":"10.1016\/j.hoc.2024.05.016_bib36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2024.05.016_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221083052","article-title":"Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials","volume":"14","author":"Witt","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.hoc.2024.05.016_bib38","doi-asserted-by":"crossref","first-page":"e390614","DOI":"10.1200\/EDBK_390614","article-title":"Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift","volume":"43","author":"Hieken","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"suppl 16","key":"10.1016\/j.hoc.2024.05.016_bib39","article-title":"The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma","volume":"40","author":"Lucas","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.016_bib40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.016_bib41","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.annonc.2020.07.016","article-title":"Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma","volume":"31","author":"Tetzlaff","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.016_bib42","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.016_bib43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.016_bib44","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"issue":"7934","key":"10.1016\/j.hoc.2024.05.016_bib45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma [published correction appears in Nature. 2023 Mar;615(7953):E23]","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.016_bib46","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.34716","article-title":"Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients","volume":"129","author":"Eroglu","year":"2023","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.016_bib47","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T\u00a0cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"issue":"7791","key":"10.1016\/j.hoc.2024.05.016_bib48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B\u00a0cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.016_bib49","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","article-title":"Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy","volume":"40","author":"Asrir","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.016_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ccell.2021.12.008","article-title":"Multi-omics prediction in melanoma immunotherapy: A new brick in the wall","volume":"40","author":"Robert","year":"2022","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.hoc.2024.05.016_bib51","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01599","article-title":"Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma","volume":"41","author":"Robert","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.016_bib52","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.016_bib53","doi-asserted-by":"crossref","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T20:24:03Z","timestamp":1725049443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858824000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0889858824000650"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.016","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in Immune Checkpoint Inhibitor for Melanoma Therapy","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}